Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: A paradigm shift that impacts current therapeutic strategies

Journal of Cell Science

Volumn 125, Issue 18, 2012, Pages 4253-4263

  Marlow, Laura A ^a   von Roemeling, Christina A ^a   Cooper, Simon J ^a   Zhang, Yilin ^a   Rohl, Stephen D ^a   Arora, Shilpi ^b   Gonzales, Irma M ^b   Azorsa, David O ^b   Reddi, Honey V ^a,c   Tun, Han W ^c   Dö ppler, Heike R ^a   Storz, Peter ^a   Smallridge, Robert C ^c   Copland, John A ^a  

^a MAYO CLINIC   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Anaplastic thyroid carcinoma; Cyclin A1; FoxO3a; Transcriptional regulation

Indexed keywords

CYCLIN A1; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHRL1;

ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THYROID CARCINOMA; UPREGULATION;

BASE SEQUENCE; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CYCLIN A1; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; THYROID NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84872188837     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.097428     Document Type: Article

References (49)

1. Azorsa, D. O., Gonzales, I. M., Basu, G. D., Choudhary, A., Arora, S., Bisanz, K. M., Kiefer, J. A., Henderson, M. C., Trent, J. M., Von Hoff, D. D. et al. (2009). Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J. Transl. Med. 7, 43.
2. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J. and Greenberg, M. E. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868.
3. Brunet, A., Park, J., Tran, H., Hu, L. S., Hemmings, B. A. and Greenberg, M. E. (2001). Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell. Biol. 21, 952-965.
4. Burgering, B. M. (2008). A brief introduction to FOXOlogy. Oncogene 27, 2258-2262.
5. Carter, M. E. and Brunet, A. (2007). FOXO transcription factors. Curr. Biol. 17, R113-R114.
6. Chan, C. B., Liu, X., Jang, S. W., Hsu, S. I. H., Williams, I., Kang, S., Chen, J. and Ye, K. (2009). NGF inhibits human leukemia proliferation by downregulating cyclin A1 expression through promoting acinus/CtBP2 association. Oncogene 28, 3825-3836.
7. Chen, J., Gomes, A. R., Monteiro, L. J., Wong, S. Y., Wu, L. H., Ng, T. T., Karadedou, C. T., Millour, J., Ip, Y. C., Cheung, Y. N. et al. (2010). Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. PLoS ONE 5, e12293.
8. Cho, N. H., Choi, Y. P., Moon, D. S., Kim, H., Kang, S., Ding, O., Rha, S. Y., Yang, Y. J. and Cho, S. H. (2006). Induction of cell apoptosis in non-small cell lung cancer cells by cyclin A1 small interfering RNA. Cancer Sci. 97, 1082-1092.
9. Edge, S. B. and Compton, C. C. (2010). The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 17:1471-1474.
10. Finnberg, N. and El-Deiry, W. S. (2004). Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: an effective multi-faceted targeting of the tumor-cell phenotype? Cancer Biol. Ther. 3, 614-616.
11. Fu, Z. and Tindall, D. J. (2008). FOXOs, cancer and regulation of apoptosis. Oncogene 27, 2312-2319.
12. Furukawa-Hibi, Y., Kobayashi, Y., Chen, C. and Motoyama, N. (2005). FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid. Redox Signal. 7, 752-760.
13. Furuyama, T., Nakazawa, T., Nakano, I. and Mori, N. (2000). Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem. J. 349, 629-634.
14. García-Rostán, G., Costa, A. M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M. J., Herrero, A., Fusco, A., Cameselle-Teijeiro, J. and Santoro, M. (2005). Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 65, 10199-10207.
15. Green, L. D., Mack, L. and Pasieka, J. L. (2006). Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies. J. Surg. Oncol. 94, 725-736.
16. Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J. and Sabatini, D. M. (2006). Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 11, 859-871.
17. Habashy, H. O., Rakha, E. A., Aleskandarany, M., Ahmed, M. A., Green, A. R., Ellis, I. O. and Powe, D. G. (2011). FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. Breast Cancer Res. Treat. 129, 11-21.
18. Hu, M. C., Lee, D. F., Xia, W., Golfman, L. S., Ou-Yang, F., Yang, J. Y., Zou, Y., Bao, S., Hanada, N., Saso, H. et al. (2004). IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117, 225-237.
19. Huang, H. and Tindall, D. J. (2007). Dynamic FoxO transcription factors. J. Cell Sci. 120, 2479-2487.
20. Hundahl, S. A., Fleming, I. D., Fremgen, A. M. and Menck, H. R. (1998). A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83, 2638-2648.
21. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J. and Su, B. (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125-137.
22. Ji, P., Agrawal, S., Diederichs, S., Bäumer, N., Becker, A., Cauvet, T., Kowski, S., Beger, C., Welte, K. and Berdel, W. E. (2004). Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells. Oncogene 24, 2739-2744.
23. Joshi, A. R., Jobanputra, V., Lele, K. M. and Wolgemuth, D. J. (2009). Distinct properties of cyclin-dependent kinase complexes containing cyclin A1 and cyclin A2.
24. Biochem. Biophys. Res. Commun. 378, 595-599. Karger, S., Weidinger, C., Krause, K., Sheu, S. Y., Aigner, T., Gimm, O., Schmid, K. W., Dralle, H. and Fuhrer, D. (2009). FOXO3a: a novel player in thyroid carcinogenesis? Endocr. Relat. Cancer 16, 189-199.
25. Lin, H., Dai, T., Xiong, H., Zhao, X., Chen, X., Yu, C., Li, J., Wang, X. and Song, L. (2010). Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS ONE 5, e15797.
26. Marlow, L. A., D'Innocenzi, J., Zhang, Y., Rohl, S. D., Cooper, S. J., Sebo, T., Grant, C., McIver, B., Kasperbauer, J. L., Wadsworth, J. T. et al. (2010). Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target. J. Clin. Endocrinol. Metab. 95, 5338-5347.
27. Neff, R. L., Farrar, W. B., Kloos, R. T. and Burman, K. D. (2008). Anaplastic thyroid cancer. Endocrinol. Metab. Clin. North Am. 37, 525-538, xi.
28. Obsil, T. and Obsilova, V. (2011). Structural basis for DNA recognition by FOXO proteins. Biochim. Biophys. Acta 1813, 1946-1953.
29. Santarpia, L., El-Naggar, A. K., Cote, G. J., Myers, J. N. and Sherman, S. I. (2008). Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 93, 278-284.
30. Schmittgen, T. D. and Livak, K. J. (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101-1108.
31. Schweppe, R. E., Klopper, J. P., Korch, C., Pugazhenthi, U., Benezra, M., Knauf, J. A., Fagin, J. A., Marlow, L. A., Copland, J. A., Smallridge, R. C. et al. (2008). Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. 93, 4331-4341.
32. Sharma, S. K., Ramsey, T. M., Chen, Y.-N. P., Chen, W., Martin, M. S., Clune, K., Sabio, M. and Bair, K. W. (2001). Identification of E2F-1/Cyclin A antagonists. Bioorg. Med. Chem. Lett. 11, 2449-2452.
33. Sherman, S. I. (2006). Anaplastic Carcinoma. Humana Press, Totowa, NJ.
34. Shin, D., Lee, M., Hong, Z. and Lee, E. (2010). The Role of Akt/PKB/FOXO3a Signaling in Growth of Follicular Thyroid Cancer. The 14th International Thyroid Congress. 14, P-0854.
35. Shukla, S., Shukla, M., Maclennan, G. T., Fu, P. and Gupta, S. (2009). Deregulation of FOXO3A during prostate cancer progression. Int. J. Oncol. 34, 1613-1620.
36. Siegel, R., Naishadham, D. and Jemal, A. (2012). Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29.
37. Singh, A., Plati, J. and Khosravi-Far, R. (2011). Harnessing the tumor suppressor function of FOXO as an alternative therapeutic approach in cancer. Curr. Drug Targets 12, 1311-1321.
38. Smallridge, R. C. and Copland, J. A. (2010). Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin. Oncol. (R. Coll. Radiol.) 22, 486-497.
39. Smallridge, R. C., Marlow, L. A. and Copland, J. A. (2009). Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 16, 17-44.
40. Stambolic, V. and Woodgett, J. R. (1994). Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem. J. 303, 701-704.
41. Storz, P. (2011). Forkhead homeobox type O transcription factors in the responses to oxidative stress. Antioxid. Redox Signal. 14, 593-605.
42. Storz, P., Döppler, H., Copland, J. A., Simpson, K. J. and Toker, A. (2009). FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases. Mol. Cell. Biol. 29, 4906-4917.
43. Tzivion, G., Dobson, M. and Ramakrishnan, G. (2011). FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim. Biophys. Acta 1813, 1938-1945.
44. van den Berg, M. C. W. and Burgering, B. M. T. (2011). Integrating opposing signals toward Forkhead box O. Antioxid. Redox Signal. 14, 607-621.
45. Vogt, P. K., Jiang, H. and Aoki, M. (2005). Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle 4, 908-913.
46. Weidinger, C., Krause, K., Klagge, A. L. and Fuhrer, D. (2010). FOXO3 is inhibited by the oncogenic p110a mutant H1074R in thyreocytes, but can be reactivated by NSAIDS. The 14th International Thyroid Congress Abstract Booklet. 14, OC-012.
47. Woyach, J. A. and Shah, M. H. (2009). New therapeutic advances in the management of progressive thyroid cancer. Endocr. Relat. Cancer 16, 715-731.
48. Yang, J. Y. and Hung, M. C. (2009). A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin. Cancer Res. 15, 752-757.
49. Yang, J. Y. and Hung, M. C. (2011). Deciphering the role of forkhead transcription factors in cancer therapy. Curr. Drug Targets 12, 1284-1290.